This Is MS Multiple Sclerosis Knowledge & Support Community

Teva Pharmaceutical Industries Ltd. and Active Biotech announced today initial results from the Phase III BRAVO study, which was designed to evaluate the efficacy, safety and tolerability of oral laquinimod compared to placebo and to provide a benefit-risk assessment comparing oral laquinimod BRAVO is the second of two pivotal Phase III studies in the clinical development program for laquinimod, an investigational, oral, once-daily therapy for the treatment of relapsing-remitting multiple sclerosis (RRMS). Results showed that the BRAVO study did not achieve its primary endpoint of reducing the annualized relapse rate (p=0.075).... Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/1735

Averaging out the numbers after the Teva two-step in explaining the results, they seem to be hovering around the same approx 33% efficacy numbers we have seen in the past.

Not too promising in the very competitive world of MS drugs.

Harry